Status: Recruiting
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Participants needed: 375
Trial details
Phase: Phase 3Age: 50-90Biological sex: AllType: InterventionalSponsor: Suven Life Sciences LimitedUpdated: Jan 12, 2026Locations: 44
Eligibility criteria
Has a diagnosis of dementia of the Alzheimer's type according to the National In... [+2]
Participants with dementia predominantly of the non-Alzheimer's type (e.g., vasc... [+2]